Caliper LS and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
News May 06, 2008
Caliper Life Sciences, Inc. has announced collaboration with DiscoveRx Corporation that enables functional cell-based G protein-coupled receptor (GPCR) assays from DiscoveRx to be performed on Caliper’s LabChip® platforms.
The combined offering bundles Caliper LabChip systems with DiscoveRx’s cellular assays, including PathHunter™ B Arrestin and cAMP Hunter™, to assist pharmaceutical and biotechnology researchers in more efficiently discovering GPCR drugs.
“This collaboration will expand the capability of Caliper’s LabChip technology into the dynamic GPCR drug discovery market, an opportunity with substantial potential due to the importance of GPCR drugs and the number of active R&D programs in neuroscience, cardiovascular, inflammation and other disease areas.
Through our collaboration with DiscoveRx, we have expanded our offerings to provide researchers with the ability to prosecute GPCR targets in a functional cellular assay for lead optimization and profiling,” said Kevin Hrusovsky, CEO of Caliper Life Sciences.
“Caliper’s LabChip platform has become the new standard for kinase assays and we have broadened the platform to enable testing of phosphodiesterases, histone deacetylases (including sirtuins) proteases, phophatases and lipid modifying enzymes. The addition of cellular GPCR assays, which are a critical linkage in translational research, expands Caliper’s in vitro-in vivo bridge and should provide our customers with enhanced ability to make more informed decisions that ultimately lead to safer and more effective drugs.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.